HG204 CRISPR-Cas13 RNA-Editing Therapy for MECP2 Duplication Syndrome: Preclinical Success to First-in-Human Study
文献类型：期刊论文
| 作者 | Yang, Dong4; Yuan, Yiqun4; Zhang, Xin4; Luk, Alvin3; Yang, Hui1,2; Shi, Linyu4 |
| 刊名 | MOLECULAR THERAPY
 |
| 出版日期 | 2025-04-28 |
| 卷号 | 33期号:4页码:3 |
| ISSN号 | 1525-0016 |
| WOS研究方向 | Biotechnology & Applied Microbiology ; Genetics & Heredity ; Research & Experimental Medicine |
| 语种 | 英语 |
| WOS记录号 | WOS:001521594200223 |
| 出版者 | CELL PRESS |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/321162]  |
| 专题 | 中国科学院上海药物研究所 |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Meteria Med, Shanghai, Peoples R China 2.HuidaGene Therapeut Co Ltd, Shanghai, Peoples R China 3.Huidagene Therapeut Inc, Clinton, NJ USA 4.HuidaGene Therapeut Co Ltd, Shanghai, Peoples R China |
| 推荐引用方式 GB/T 7714 | Yang, Dong,Yuan, Yiqun,Zhang, Xin,et al. HG204 CRISPR-Cas13 RNA-Editing Therapy for MECP2 Duplication Syndrome: Preclinical Success to First-in-Human Study[J]. MOLECULAR THERAPY,2025,33(4):3. |
| APA | Yang, Dong,Yuan, Yiqun,Zhang, Xin,Luk, Alvin,Yang, Hui,&Shi, Linyu.(2025).HG204 CRISPR-Cas13 RNA-Editing Therapy for MECP2 Duplication Syndrome: Preclinical Success to First-in-Human Study.MOLECULAR THERAPY,33(4),3. |
| MLA | Yang, Dong,et al."HG204 CRISPR-Cas13 RNA-Editing Therapy for MECP2 Duplication Syndrome: Preclinical Success to First-in-Human Study".MOLECULAR THERAPY 33.4(2025):3. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。